Baxter International has signed an agreement to acquire Somatogen in a stock merger worth an estimated $189 million. Somatogen is developing recombinant haemoglobin products and the acquisition will add to Baxter's expertise in the field of oxygen-carrying "blood substitutes".
Baxter is offering $9 per Somatogen share in Baxter stock, plus a cash milestone of up to $2 per share...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?